CP and fragile X syndrome: A larger proportion of FXS NPCs responded to Naspm trihydrochloride (Naspm; a Glu2-lacking CP-AMPAR inhibitor) treatment, also supporting that there are elevated levels of this AMPA receptor type in the FXS group.